Imiquimod · Zyclara, NSC-369100

What is Imiquimod?

Imiquimod is a topical cream applied to treat actinic keratoses and external genital warts. Its mechanism of action is unknown. It is studied in vulvar intraepithelial neoplasia and HPV-related lesions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Zyclara, NSC-369100, NSC-759651, R-837

Drug type

Small molecule

Therapy area

Dermatology

Developer

Bausch

In trials of

INO

FDA status

Approved as Zyclara (February 27, 1997), NDA020723 · FDA label

UNII

P1QW714R7M

✅ FDA-approved uses

• Actinic keratoses (AK) of the face or balding scalp
• External genital and perianal warts (EGW)

From the indications section of the FDA label (version of May 23, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Human Papillomavirus (HPV)Pre-cancerous Lesions of the VulvaVIN2VIN3Vulvar DysplasiaVulvar High Grade Squamous Intraepithelial Lesion (HSIL)Vulvar Intraepithelial Neoplasia (VIN)

Sources

• FDA label (DailyMed)
• FDA label Imiquimod (2025-06-30), indications
• FDA label Zyclara (2025-05-23), indications
• ClinicalTrials.gov NCT03180684

Updated Oct 3, 2026.